Astrocytoma Clinical Trials

15 recruiting

Astrocytoma Trials at a Glance

59 actively recruiting trials for astrocytoma are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 1 with 24 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running astrocytoma studies include M.D. Anderson Cancer Center, National Cancer Institute (NCI), and Nationwide Children's Hospital.

Browse astrocytoma trials by phase

Treatments under study

About Astrocytoma Clinical Trials

Looking for clinical trials for Astrocytoma? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Astrocytoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Astrocytoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 59 trials

Recruiting
Phase 3

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Low Grade Astrocytoma
National Cancer Institute (NCI)170 enrolled132 locationsNCT04166409
Recruiting
Phase 1Phase 2

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled17 locationsNCT05765812
Recruiting
Not Applicable

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

Diffuse Astrocytoma, IDH-MutantOligodendrogliomaOligodendroglioma, Anaplastic
Oslo University Hospital225 enrolled1 locationNCT05190172
Recruiting
Phase 1

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

GlioblastomaAstrocytomaProgressive Disease
Masonic Cancer Center, University of Minnesota9 enrolled1 locationNCT07560865
Recruiting
Not Applicable

Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

GliomaPilocytic AstrocytomaPleomorphic Xanthoastrocytoma+2 more
St. Jude Children's Research Hospital74 enrolled2 locationsNCT04065776
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 1

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

GlioblastomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more
University of Nebraska24 enrolled1 locationNCT05698524
Recruiting
Phase 2

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Brain TumorBrain CancerGlioblastoma+6 more
Northwell Health37 enrolled1 locationNCT02800486
Recruiting
Phase 1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Resectable GlioblastomaIDH Wildtype GlioblastomaRecurrent Astrocytoma+2 more
Jonsson Comprehensive Cancer Center10 enrolled1 locationNCT07089641
Recruiting
Phase 2

Tuvusertib in Astrocytoma With ATRX Mutation

Astrocytoma
Grupo Español de Investigación en Neurooncología56 enrolled10 locationsNCT07417761
Recruiting
Phase 1

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 3

Vorasidenib Maintenance for IDH Mutant Astrocytoma

IDH-mutant Grade 2 or 3 Astrocytoma
European Organisation for Research and Treatment of Cancer - EORTC468 enrolled33 locationsNCT06809322
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 1Phase 2

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Glioblastoma MultiformeAstrocytoma, Grade III
David Baskin MD62 enrolled1 locationNCT03596086
Recruiting
Phase 1Phase 2

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

GlioblastomaAnaplastic Astrocytoma
The Methodist Hospital Research Institute62 enrolled1 locationNCT03603405
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled17 locationsNCT06894979